Companies/HK/2162

KEYMED BIOSCIENCES INC. · 康诺亚-B

Last · HKSEHK$76.15-1.00 (-1.30%)live · yahoo · 1h ago
Vol 1.87M ≈ 142.33M
Market capHK$22.4B294.6M sh
P/E · TTM25.8fwd 185 · eps 2.95
Beta-0.16vs S&P 500
Div yield0.00%annual · TTM
52w range
HK$44.66HK$89.75
Volume1.9Msession

Issuer

Legal nameKEYMED BIOSCIENCES INC. · 康诺亚-B
HQHong Kong (HK)
ListingHK 2162
ISINKYG5252B1023
LEI549300600S6M6SOT7P36
SectorHealthcare
IndustryBiotechnology & Medical Research
CurrencyCNY
Entity registrylei:549300600S6M6SOT7P36
Org ID9900052638
Websiteen.keymedbio.com
Employees1,625
AddressKeymed Biosciences, Inc. Tianfu International Bio-Town 610219, Chengdu +86 28 8861 0620
Headline financial metrics
Revenue¥834.6M
PeriodTTM 2026-06-30
Loading chart…

OpenFilings analyst

Our analyst

10-K · 2026-04-29

From latest 10-K · 2026-04-29

  • Net Margin Sharply Negative
  • Rd Intensity High

Red flags

  • Net Margin Sharply Negative — Net margin -73.0%
  • Rd Intensity High — R&D/Revenue 101.0%

Documents

FormReporting forFiledFlags
DISCLOSURE非执行董事辞任
2026-09-062026-09-060
DISCLOSURE董事名单及其角色和职能
2026-09-062026-09-060
就司普奇拜单抗注射液东南亚和中亚等18个国家和地区上市注册和商业化达成许可协议自愿性公告 - 就司普奇拜单抗注射液东南亚和中亚等18个国家和地区上市注册和商业化达成许可协议
2026-09-022026-09-020
DISCLOSURE截至二零二六年八月三十一日止月份之股份发行人的证券变动月报表
2026-09-022026-09-020
DISCLOSURE内幕消息 -建议发行人民币股份及于上海证券交易所科创板上市
2026-08-192026-08-190
Showing 5 of 23 filings